Bedside Rapid Flu Test and Zanamivir Prescription in Healthy Working Adults: A Cost-Benefit Analysis

Author： Schwarzinger M.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.21, Iss.3, 2003-01, pp. : 215-224

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Flu vax cost effective in healthy adults aged 50−64 years

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 499, 2006-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Cost-Benefit Analysis of Amtolmetin-Guacil

By Belisari A.   Mantovani L.G.  

Clinical Drug Investigation, Vol. 21, Iss. 1, 2001-01 ,pp. : 47-58

Adis International

Access to resources Recommend Favorite

Analysis suggests zanamivir first choice for 'flu in Japan

By  

Inpharma, Vol. 1, Iss. 1472, 2005-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite

An introduction to cost-effectiveness and cost–benefit analysis of pharmacogenomics

By Phillips Kathryn A   Veenstra David   Bebber Stephanie Van   Sakowski Julie  

Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. : 231-239

Future Medicine

Access to resources Recommend Favorite

A cost–benefit analysis of chemotherapy for gastric cancer

By Galizia Eva   Berardi Rossana   Scartozzi Mario   Cascinu Stefano  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 10, 2004-10 ,pp. : 2109-2114

Informa Healthcare

Access to resources Recommend Favorite